Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/26458
Title: | Which Factors Predict Overall Survival in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Abiraterone Acetate Post-Docetaxel? | Authors: | Van Praet, Charles Rottey, Sylvie Van Hende, Fransien Pelgrims, Gino Demey, Wim Van Aelst, Filip Wynendaele, Wim Gil, Thierry Schatteman, Peter Filleul, Bertrand Schallier, Denis Machiels, Jean-Pascal Schrijvers, Dirk Everaert, Els D'Hondt, Lionel Werbrouck, Patrick Vermeij, Joanna MEBIS, Jeroen Clausse, Marylene Rasschaert, Marika Van Erps, Joanna Verheezen, Jolanda Van Haverbeke, Jan Goeminne, Jean-Charles Lumen, Nicolaas |
Issue Date: | 2017 | Source: | CLINICAL GENITOURINARY CANCER, 15(4), p. 502-508 | Abstract: | Individual patients' survival varies greatly in metastatic castration-resistant prostate cancer. Retrospective analysis of 368 patients treated with docetaxel and starting abiraterone acetate revealed 5 adverse prognostic factors: hemoglobin < 12 g/dL, > 10 metastases, ECOG performance status >= 2, radiographic progression, and time since diagnosis < 90 months. A prognostic model stratifies patients into 3 groups with different estimated survival, which can aid in patient counseling.Abiraterone acetate (AA) increases overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel. However, survival time varies substantially between individuals. Our goal was to identify prognostic factors that better estimate OS. Materials and Methods: This is a retrospective multicentric analysis of 368 patients with mCRPC starting AA with prednisone after docetaxel. Cox proportional hazards statistics were applied. A multivariate model was constructed based on significant univariate predictors by using a manual stepwise forward and backward selection strategy. Model performance was determined by using receiver operating characteristic (ROC) curves. Results: Univariate analysis identified 20 significant OS predictors. A multivariate model was constructed, based on 220 patients, incorporating 5 independent risk factors for decreased OS at the time of AA initiation: hemoglobin <12 g/dL (hazard ratio [HR] 2.02), > 10 metastases (HR 1.80), ECOG performance status >= 2 (HR 1.88), radiographic progression (HR 1.50), and time since diagnosis < 90 months (HR 1.66, all P <.05). Patients were stratified into 3 groups: good (0-2 risk factors, median OS 22.6 months), intermediate (3 risk factors, median OS 13.9 months), and poor prognosis (4-5 risk factors, median OS 6.2 months). The area under the ROC curve based on the event "death by the time of median OS (13.3 months)" was 0.736 (95% confidence interval 0.670-0.803). Conclusion: We identified 5 readily available risk factors independently associated with decreased OS. The resulting model may be used for patient counseling in daily clinical practice, as well as patient stratification in clinical trials. (C) 2017 Elsevier Inc. All rights reserved. | Keywords: | chemotherapy; prognosis; prostatic neoplasms; steroids; survival | Document URI: | http://hdl.handle.net/1942/26458 | ISSN: | 1558-7673 | e-ISSN: | 1938-0682 | DOI: | 10.1016/j.clgc.2017.01.019 | ISI #: | 000407736900041 | Rights: | (C) 2017 Elsevier Inc. All rights reserved. | Category: | A1 | Type: | Journal Contribution |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
VanPraet.pdf Restricted Access | Published version | 313.98 kB | Adobe PDF | View/Open Request a copy |
SCOPUSTM
Citations
6
checked on Sep 5, 2020
WEB OF SCIENCETM
Citations
8
checked on Oct 14, 2024
Page view(s)
52
checked on Jun 14, 2022
Download(s)
40
checked on Jun 14, 2022
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.